` EXAI (Exscientia PLC) vs S&P 500 Comparison - Alpha Spread

EXAI
vs
S&P 500

Over the past 12 months, EXAI has underperformed S&P 500, delivering a return of -10% compared to the S&P 500's 9% growth.

Stocks Performance
EXAI vs S&P 500

Loading
EXAI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
EXAI vs S&P 500

Loading
EXAI
S&P 500
Difference
www.alphaspread.com

Performance By Year
EXAI vs S&P 500

Loading
EXAI
S&P 500
Add Stock

Competitors Performance
Exscientia PLC vs Peers

S&P 500
EXAI
ABBV
AMGN
GILD
VRTX
Add Stock

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.59 USD
Overvaluation 5%
Intrinsic Value
Price
Back to Top